Latest
News

2024

• 2023

  • November 9, 2023
    Chitogenx demonstrates ortho-r efficacy and osteoarthritis protection in large animal meniscal repair study

    Read Article

  • November 7, 2023
    Chitogenx launches burn and skin repair development program

    Read Article

  • September 29, 2023
    Chitogenx reports second quarter 2024 results

    Read Article

  • September 28, 2023
    Chitogenx receives notice of allowance for key patent in united states and canada

    Read Article

  • September 26, 2023
    Chitogenx concludes enrolment for its u.s. phase i/ii rotator cuff tear repair clinical trial

    Read Article

  • August 2, 2023
    Chitogenx announces voting results of its annual general meeting of shareholders

    Read Article

  • June 30, 2023
    Chitogenx reports first quarter 2024 results

    Read Article

  • June 15, 2023
    Chitogenx retains bruder consulting & venture group to broaden and accelerate ongoing strategic development partnership discussions

    Read Article

  • June 5, 2023
    Chitogenx closes $288,000 second tranche of non-brokered private placement offering

    Read Article

  • May 31, 2023
    Chitogenx reports 2023 fiscal year-end results

    Read Article

  • May 5, 2023
    Chitogenx closes $3.9 million non-brokered private placement offering

    Read Article

  • May 1, 2023
    Chitogenx amends terms of previously announced non-brokered private placement

    Read Article

  • April 14, 2023
    Chitogenx announces change of auditors

    Read Article

  • April 4, 2023
    Chitogenx announces new $2.5 million non-brokered private placement offering and balance sheet restructuring

    Read Article

  • February 16, 2023
    Chitogenx announces $3.5 million grant to advance ortho-r commercial development

    Read Article

  • February 14, 2023
    Chitogenx demonstrates ortho-r residency properties in meniscus study

    Read Article

  • February 9, 2023
    Chitogenx announces up to $4.35 million private placement pursuant to the listed issuer exemption

    Read Article
• 2022

  • December 29, 2022
    Chitogenx reports its third quarter 2023 results

    Read Article

  • November 9, 2022
    Chitogenx successfully completes initial portion of its u.s. phase i/ii rotator cuff repair clinical trial

    Read Article

  • October 19, 2022
    Chitogenx signs memorandum of understanding with california medical innovations institute (calmi2)

    Read Article

  • October 13, 2022
    Chitogenx launches second orthopedic development program in meniscus repair

    Read Article

  • October 5, 2022
    Chitogenx to pursue sales of medical grade chitosan as new near-term revenue initiative

    Read Article

  • September 29, 2022
    Chitogenx reports its second quarter 2023 results

    Read Article

  • September 7, 2022
    Ortho regenerative technologies announces corporate name change to chitogenx

    Read Article

  • July 27, 2022
    Ortho regenerative technologies announces enrollment of first patient in its u.s. phase i/ii rotator cuff tear repair clinical trial

    Read Article

  • July 22, 2022
    Ortho regenerative technologies announces voting results of its annual general and special meeting of shareholders

    Read Article

  • June 24, 2022
    Ortho regenerative technologies reports its first quarter 2023 results

    Read Article

  • June 13, 2022
    Ortho regenerative technologies initiates patients recruitment for its u.s. phase i/ii rotator cuff tear repair clinical trial

    Read Article

  • May 26, 2022
    Ortho regenerative technologies receives $500,000 axelys grant to advance ortho-m development for meniscus repair

    Read Article

  • May 20, 2022
    Ortho regenerative technologies reports its fourth quarter and 2022 year-end results

    Read Article

  • May 4, 2022
    Ortho regenerative technologies receives key u.s. composition and method patent for ortho-r soft tissue repair platform

    Read Article

  • April 6, 2022
    Ortho regenerative technologies closes oversubscribed non-brokered private placement for $3.2 million

    Read Article

  • March 24, 2022
    Ortho regenerative technologies to participate in the 2022 virtual growth conference presented by maxim group llc and hosted by m-vest

    Read Article

  • March 21, 2022
    Ortho regenerative technologies amends the terms of its $3 million non-brokered private placement of units

    Read Article

  • March 15, 2022
    Ortho regenerative technologies announces executive leadership changes

    Read Article

  • February 11, 2022
    Ortho regenerative technologies announces $3 million non-brokered private placement of units

    Read Article

  • February 7, 2022
    Ortho regenerative technologies enters into a material transfer agreement with a global strategic medical company for its ortho-r rotator cuff tear repair phase i/ii u.s. clinical trial

    Read Article
• 2021

  • December 21, 2021
    Ortho regenerative technologies reports its third quarter 2022 results

    Read Article

  • December 13, 2021
    Ortho regenerative technologies closes non-brokered $1.05 million private placement

    Read Article

  • December 13, 2021
    Ortho regenerative technologies announces u.s. ind clinical hold lifted by the fda & clearance to proceed with u.s. clinical trial

    Read Article

  • November 12, 2021
    Ortho regenerative technologies announces filing of response to type a meeting with fda and non-brokered $1.5 million private placement

    Read Article

  • October 6, 2021
    Ortho regenerative technologies announces successful type a meeting with u.s. fda on cmc elements for which more information was required to clear ind clinical hold

    Read Article

  • September 30, 2021
    Ortho regenerative technologies reports its second quarter 2022 results

    Read Article

  • August 20, 2021
    Ortho regenerative technologies announces extension of fda clinical hold of ortho-r investigational new drug application

    Read Article

  • July 21, 2021
    Ortho regenerative technologies announces voting results of its annual general and special meeting of shareholders

    Read Article

  • July 20, 2021
    Ortho regenerative technologies submits formal response to u.s. fda clinical hold

    Read Article

  • July 19, 2021
    Ortho regenerative technologies announces amendments and extension of unsecured convertible debentures and warrants

    Read Article

  • June 29, 2021
    Ortho regenerative technologies reports its first quarter 2022 results

    Read Article

  • June 15, 2021
    Ortho regenerative technologies appoints two new members to its board of directors

    Read Article

  • June 4, 2021
    Ortho regenerative technologies receives clinical hold letter from the u.s. fda

    Read Article

  • June 1, 2021
    Ortho regenerative technologies reports its fourth quarter and 2021 year-end results

    Read Article

  • April 6, 2021
    Ortho regenerative technologies announces submission of investigational new drug application for ortho-r

    Read Article

  • March 31, 2021
    Ortho regenerative technologies secures dtc eligibility for the trading of its shares on the us otcqb market

    Read Article

  • March 2, 2021
    Ortho regenerative technologies well-positioned for next phase of development

    Read Article

  • February 24, 2021
    Ortho regenerative technologies adds patrick o’donnell to board of directors

    Read Article

  • February 10, 2021
    Ortho regenerative technologies launches agoracom platform for online investors outreach

    Read Article

  • February 4, 2021
    Ortho regenerative technologies retains westwicke icr as investor relations advisors for the u.s.

    Read Article

  • January 5, 2021
    Ortho regenerative technologies enters into global license with hanuman pelican, inc.

    Read Article
• 2020

  • December 18, 2020
    Ortho regenerative technologies reports its third quarter 2021 results

    Read Article

  • December 3, 2020
    Ortho regenerative technologies completes non-brokered $3.0 million private placement

    Read Article

  • October 28, 2020
    Ortho regenerative technologies begins trading on the otcqb u.s. market

    Read Article

  • October 19, 2020
    Ortho regenerative technologies announces the nomination of its new vice-president clinical and medical affairs

    Read Article

  • September 25, 2020
    Ortho regenerative technologies reports its second quarter 2021 results

    Read Article

  • September 2, 2020
    Ortho regenerative technologies completes additional private placement

    Read Article

  • August 31, 2020
    Ortho regenerative technologies announces non-brokered private placement of units

    Read Article

  • August 24, 2020
    Ortho regenerative technologies closes non-brokered $2.5 million private placement

    Read Article

  • August 6, 2020
    Ortho regenerative technologies announces fda regulatory designation and jurisdictional assignment for ortho-r

    Read Article

  • July 24, 2020
    Ortho regenerative technologies announces non-brokered private placement of units

    Read Article

  • July 23, 2020
    Ortho regenerative technologies releases new positive histology results from pivotal preclinical glp rotator cuff tear repair efficacy study in large-animal model

    Read Article

  • June 30, 2020
    Ortho regenerative technologies reports its first quarter 2021 results

    Read Article

  • June 22, 2020
    Ortho regenerative technologies announces the nomination of a new independent chairman of the board

    Read Article

  • May 29, 2020
    Ortho regenerative technologies reports its fourth quarter and 2020 year-end results

    Read Article

  • May 20, 2020
    Ortho regenerative technologies enters into licensing agreement to expand the scope of its technological platform applications

    Read Article

  • April 22, 2020
    Ortho regenerative technologies advances ortho-r regulatory and clinical projects with $1.1 million private placement

    Read Article

  • March 12, 2020
    Ortho regenerative technologies announces positive results from pivotal preclinical study in rotator cuff tear repair

    Read Article
• 2019

  • December 31, 2019
    Ortho regenerative technologies reports its third quarter 2020 financial results

    Read Article

  • December 30, 2019
    Ortho regenerative technologies announces non-brokered private placement of convertible debenture units

    Read Article

  • December 12, 2019
    Ortho rti announces extension of certain early warrants

    Read Article

  • October 15, 2019
    Ortho rti announces extension of certain early warrants

    Read Article

  • October 9, 2019
    Ortho regenerative technologies closes $1.6 million private placement

    Read Article

  • October 1, 2019
    Ortho regenerative technologies reports its second quarter 2020 financial results

    Read Article

  • September 12, 2019
    Ortho regenerative technologies selects us based specialized cro, mcra llc, for its upcoming phase i/ii rotator cuff human trial

    Read Article

  • September 10, 2019
    Ortho regenerative technologies to present at the fall investor summit on september 17, 2019 in new york city

    Read Article

  • August 28, 2019
    Ortho regenerative technologies announces collaborative agreement with leading global orthopaedic company

    Read Article

  • August 14, 2019
    Ortho regenerative technologies provides business update on its ortho-r rotator cuff program

    Read Article

  • August 5, 2019
    Ortho rti announces extension of certain early warrants

    Read Article

  • July 3, 2019
    Ortho regenerative technologies reports its first quarter 2020 financial results and announces non-brokered private placement

    Read Article

  • June 20, 2019
    Ortho regenerative technologies appoints pierre laurin to its board of directors

    Read Article

  • June 17, 2019
    Ortho regenerative technologies announces changes in executive leadership

    Read Article

  • February 27, 2019
    Ortho rti confirms timeline to initiate human clinical program after meeting with the fda

    Read Article

  • February 11, 2019
    Ortho rti announces initiation of pivotal study on ortho-r for rotator cuff repair

    Read Article

  • February 4, 2019
    Ortho rti announces more prestigious scientific validation

    Read Article
• 2018

  • December 13, 2018
    Ortho rti's data selected for podium presentation at international conference.

    Read Article

  • October 10, 2018
    Evidence on the safety and efficacy of ortho-r in a large animal model presented at 2018 sicot world congress.

    Read Article

  • September 19, 2018
    Ortho regenerative technologies inc. appoints accomplished life science executive, luc mainville, as cfo.

    Read Article

  • September 6, 2018
    Ortho rti signs agreement with a leading cmo for the manufacture of cgmp finished dosage form ortho-r in preparation for planned first-in-human study.

    Read Article

  • August 31, 2018
    Ortho regenerative technologies inc. announces cfo change

    Read Article

  • July 31, 2018
    Ortho rti announces extension of certain early warrants

    Read Article

  • July 19, 2018
    Ortho rti announces closing of second tranche of non-brokered private placement

    Read Article

  • June 13, 2018
    Ortho rti press release histopathology

    Read Article

  • May 31, 2018
    Ortho rti announces the issuance of 3,610,000 shares pursuant to its non-brokered private placement

    Read Article

  • May 25, 2018
    Ortho rti announces non-brokered private placement

    Read Article

  • May 23, 2018
    Ortho rti receives notice of allowance for second european patent protecting ortho-r technology

    Read Article

  • April 2, 2018
    Ortho rti announces compelling data from ortho-r pilot study in rotator cuff repair

    Read Article

  • March 8, 2018
    Ortho rti receives notice of allowance for european patent protecting ortho-r technology

    Read Article

  • January 8, 2018
    Ortho rti announces changes to its board of directors

    Read Article
• Older

  • October 18, 2016
    Ortho announces changes in executive leadership

    Read Article

  • August 26, 2016
    Ortho regenerative technologies inc. announces receiving key patent

    Read Article

  • August 3, 2016
    Ortho announces a private placement and closing of first tranche

    Read Article

  • June 30, 2016
    Ortho grants of options and appoints new cfo

    Read Article

  • May 20, 2016
    Ortho regenerative technologies inc. presents advances in tissue repair in multiple podium presentations and posters at the 2016 world biomaterials congress

    Montreal, Canada, May 20^th, 2016 - Ortho Regenerative Technologies Inc., a regenerative medical device company specializing in the repair of sports medicine injuries (the “Company”), announced today the presentation key technical advances in the mechanisms underlying the repair of soft tissue injuries through its proprietary biopolymer in 4 podium presentations and 2 poster presentations at the World Biomaterials Congress being held in Montreal, Canada from May 17-22, 2016.

  • December 9, 2015
    Manitex capital inc. affiliate, ortho regenerative technologies inc., announces the appointment of dr. ed margerrison as president and ceo

    Read Article